Agoracom: Small Cap Investment - Zenith Epigenetics - Re: News out - Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIV

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

LongRVXer

Rank: Treasurer [?]

Points: 550 [?]

Votes: 12 Score: 4.1 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: News out - Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIV

in response to

News out - Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIV

LongRVXer

posted on Feb 22, 2022 09:12AM

I just looked a little deeper in BristolMyers Squibb's portfolio and it appears, in my opinion, that they perfectly align to our little company.

Main focus

Cardiovascular diseases,

Diabetes mellitus

Infectious diseases, including HIV Infection and associated conditions,

Inflammatory disorders

Regards,

Long - dyodd

5 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply